Durham, NC, United States of America

Frank Ivy Carroll

USPTO Granted Patents = 46 


 

Average Co-Inventor Count = 3.1

ph-index = 14

Forward Citations = 445(Granted Patents)


Location History:

  • Durham, NC (US) (1983 - 2017)
  • Durham, NJ (US) (2021)
  • Research Triangle Park, NC (US) (2002 - 2022)

Company Filing History:


Years Active: 1983-2022

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Kappa Opioid Antagonists
Monoamine Reuptake Inhibitors
Arylpiperazine Compounds
Nicotinic Receptor Compounds
Opioid Receptor Modulators
Cocaine Receptor Binding Ligands
Monoclonal Antibody Antagonists
Opiate Compounds
Dopamine Transporter Imaging Ligand
Methamphetamine-like Haptens
Smoking Cessation Methods
Biogenic Amine Transporters
46 patents (USPTO):Explore Patents

Title: **Frank Ivy Carroll: Innovations in Pharmacotherapy**

Introduction

Frank Ivy Carroll, a prolific inventor based in Durham, NC, has made significant contributions to the field of pharmacotherapy, holding an impressive 46 patents throughout his career. His work focuses on developing compounds aimed at treating various mental health disorders and addictions, showcasing a commitment to improving the lives of those affected by these issues.

Latest Patents

Among his latest innovations, Carroll has developed substituted 1,2,3,4-tetrahydroisoquinolines, which act as kappa opioid antagonists. These compounds are noted for their potential as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addictions to substances such as cocaine, methamphetamine, nicotine, alcohol, and opiates. This patent underscores the importance of selective kappa opioid receptor antagonist compounds and their pharmaceutical applications in addressing critical mental health challenges.

Additionally, Carroll’s invention of monoamine reuptake inhibitors presents bupropion analogue compounds designed to inhibit the reuptake of various monoamines. These compounds selectively bind to monoamine transporters, including those for dopamine, norepinephrine, and serotonin. The implications of this research are significant, as these compounds may be utilized in treating conditions responsive to monoamine reuptake inhibition, including addiction, depression, and obesity.

Career Highlights

Carroll's career has been marked by his affiliation with esteemed research institutions such as the Research Triangle Institute and the University of Arkansas. His contributions to research in pharmacotherapy are recognized within the scientific community and underscore the impact of his inventions on modern medicine.

Collaborations

Throughout his journey, Carroll has collaborated with notable professionals in the field, including Philip Abraham and Anita H. Lewin. These partnerships have further advanced the research and development of his innovative compounds, allowing for deeper exploration of their therapeutic potential.

Conclusion

Frank Ivy Carroll’s impressive portfolio of patents reflects his dedication to addressing complex health issues through innovative pharmacological research. His continued work in the field promises to contribute further to the advancement of effective treatments for mental health disorders and addictions, signifying a lasting impact on both the scientific community and the lives of patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…